06:47 AM EDT, 07/24/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended a marketing authorization for Roche's (RO.SW) Susvimo to treat patients with neovascular age-related macular degeneration. The positive recommendation was based on data from three clinical studies, including the Archway pivotal Phase 3 study and two supportive studies, according to a Friday release. The Swiss drugmaker said Susvimo is delivered through its refillable Contivue eye implant, making it the first continuous drug-delivery treatment to offer an alternative to frequent eye injections for the disease. The European Commission is expected to make a final decision in the near future.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.